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In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically
reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was
reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-
pump inhibitor with another but not with a histamine type-2 receptor antagonist.The association between proton-pump inhibitors
and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them:
6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found
that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a
relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal
magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship
betweenmagnesiummetabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors
may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.
1. Introduction
First introduced in the late 1980s, proton-pump inhibitors
are widely used for the management of conditions related
to gastric acid secretion such as duodenal and gastric ulcer,
reflux esophagitis, and gastroesophageal reflux disease [1].
The cases of two patients developing severe hypomagne-
semia alongwith hypocalcemia and hypokalemia while being
on long-term treatment with a proton-pump inhibitor and
resolution after withdrawal were first described in 2006 [2].
Following the initial recognition, the association has been
subsequently confirmed in various reports [3]. We system-
atically reviewed and analyzed the available literature. Our
aims were to describe in detail this electrolyte abnormality, to
address the underlying mechanisms, and to warn physicians
about its occurrence.
2. Methods
Between May and October 2014, two of the authors
(Simone Janett, Pietro Camozzi) independently conducted a
computer-based research of the terms “proton-pump inhib-
itor[s],” “dexlansoprazole,” “omeprazole,” “esomeprazole,”
“lansoprazole,” “pantoprazole,” “rabeprazole,” and “hypo-
magnes[a]emia” or “magnesium” in the U.S. National Library
of Medicine database and in the Web-based Google search
engine. For this purpose, we used the principles established
by the UK Economic and Social Research Council guidance
on the conduct of narrative synthesis and on the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
statement. Reports available as an article or as a letter
in Dutch, English, French, German, Italian, Portuguese,
or Spanish were retained for the analysis. To ensure that
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the search included all published cases, cross-citation
screening was manually performed in the references of the
included articles. Poorly documented case reports and cases
with electrolyte abnormalities secondary to proton-pump
inhibitor associated kidney injury were not included [4].
From each individually described patient with hypomag-
nesemia (<0.75mmol/L) on proton-pump inhibitor treat-
ment, we made attempts to obtain the following data: gender;
age; details and duration of medication; concurrent condi-
tions or management with drugs inducing hypomagnesemia;
and laboratory findings regarding magnesium (including
changes after withdrawal and rechallenge with a different
proton-pump inhibitor or with a histamine type-2 receptor
antagonist), calcium, parathyroid hormone and potassium
blood levels, and urine magnesium excretion. From case-
control, cross-sectional studies, we collected the following
information: study setting; year of publication; origin of
the report; number of patients and details; magnesium
level; comorbidities and concurrent medications. Finally, we
reviewed the United States Food and Drug Administration
data on hypomagnesemia as adverse event reported during
the use of proton-pump inhibitors.
Numerical data are presented asmedian and interquartile
range and categorical data as relative frequency. Linear
regressions with the rank correlation coefficient 𝑟
𝑠
were
performed for analysis. Significance was assumed when 𝑃 <
0.05.
3. Results
3.1. Search Results. The initial search revealed 534 publi-
cations, of which 260 remained after excluding duplicates
(Figure 1). Ninety were reviewed in detail and 56 retained
for the final analysis. Four pertinent reports were found in
the references of the mentioned reports. Hence, in the final
analysis [2, 5–63], we included a total of 60 reports (48 in
English, 6 in Spanish, 3 in French, 1 in Dutch, 1 in German,
and 1 in Italian) from the United Kingdom (𝑁 = 12), the
United States of America (𝑁 = 9), Spain (𝑁 = 7), the
Netherlands (𝑁 = 4), Brazil (𝑁 = 3), France (𝑁 = 3), Italy
(𝑁 = 3), Switzerland (𝑁 = 3), Australia (𝑁 = 2), Belgium
(𝑁 = 2), Canada (𝑁 = 2), Germany (𝑁 = 2), Korea (𝑁 = 2),
Argentina (𝑁 = 1), Greece (𝑁 = 1), Israel (𝑁 = 1), Japan
(𝑁 = 1), New Zealand (𝑁 = 1), and Turkey (𝑁 = 1).
They were 45 reports detailing individual cases [2, 19–62],
14 case-control, cross-sectional studies [5–18] and one report
based on the United States Food and Drug Administration
data [63]. The case of a Spanish patient reported twice in the
literature was considered only once [33, 34].
3.2. Individual Cases. The 45 reports detailing cases
of proton-pump inhibitor associated hypomagnesemia
included a total of 64 individual cases. The characteristics
of the patients (30 male and 34 female subjects) appear
in Table 1. The age of 53 (83%) of the 64 patients ranged
between 50 and 80 years. Hypomagnesemia was rather
severe: it ranged between 0.03 and 0.71, with median
0.21mmol/L and was ≤0.50mmol/L in 62 (97%) cases. The
Records identified through search 
in the U.S. National Library of 
Records identified through search 
in the search engine Google 
Medicine database (N = 361)
Records searched after duplicates removed (N = 260)
Records excluded after title and abstract review (N = 170)
Citations assessed in detail for eligibility (N = 90)
Eligible reports (N = 60)
Article not pertaining (N = 34)
Reports found in reference lists (N = 4)
Scholar (N = 173)
Figure 1: Flowchart of the literature search process. Five of the 60
eligible reports had been identified exclusively from the Web-based
search engine Google Scholar.
Table 1: Clinical and laboratory findings in 64 patients with hypo-
magnesemia (<0.75mmol/L) while being on long-term manage-
ment with a proton-pump inhibitor. Numerical data are presented
as median and interquartile range (which extends from the value at
centile 25 to that at centile 75 and includes half of the data points)
and categorical data as relative frequency.
Age, years 66 [59–73]
Gender, D/C 30/34
Circulating magnesium level, mmol/L 0.24 [0.15–0.30]
Duration of treatment with
proton-pump inhibitor, years 4 [3–10]
Urinary magnesium excretion,
low/normal 42/0
Circulating calcium level, low/normal 58/2
Parathyroid hormone level‡,
low-normal/high 42/2
Circulating potassium level,
low∗/normal 27/4
‡Assessed exclusively in subjects with total calcium level <2.20mmol/L.
∗
<3.5mmol/L.
duration of treatment with a proton-pump inhibitor was one
year ormore in all cases with the exception of a newborn baby
with gastroesophageal reflux on lansoprazole, and 3 years or
more in 75% of the cases. When measured, hypomagnesemia
was always accompanied by hypomagnesiuria. Moreover,
it was very often accompanied by blood calcium level
<2.20mmol/L (97%), low or normal parathyroid hormone
levels (95%), and blood potassium level <3.50mmol/L
(87%). Linear regression analysis did not show an association
between the degree of hypomagnesemia with the degree of
hypocalcemia or hypokalemia (Figure 2). Further possible
causes of hypomagnesemia were observed in at least 21 cases:
treatment with either thiazide (𝑁 = 7) or loop diuretic
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Figure 2: Relationship between circulatingmagnesium and total calcium (left panel) or potassium (right panel) in patients with proton-pump
inhibitor associated hypomagnesemia. None of the correlations was found to be significant. The horizontal dotted lines denote the threshold
level of hypocalcemia (2.20mmol/L) and hypokalemia (3.5mmol/L), respectively.
(𝑁 = 6), alcohol abuse (𝑁 = 5), poor renal function (𝑁 = 2),
and small bowel resection (𝑁 = 1).
The following proton-pump inhibitors were used in
the 64 patients: omeprazole, esomeprazole, the S-isomer of
omeprazole, or both (𝑁 = 52); pantoprazole (𝑁 = 6);
lansoprazole (𝑁 = 3); omeprazole and lansoprazole (𝑁 = 1);
rabeprazole (𝑁 = 2). No cases of hypomagnesemia were
reported on dexlansoprazole. Hypomagnesemia resolved
after discontinuing the proton-pump inhibitor but recurred
following replacement with another proton-pump inhibitor
in at least 13 cases. In these cases, the initially used proton-
pump inhibitor was replaced as follows: with omeprazole or
esomeprazole (𝑁 = 4); with lansoprazole (𝑁 = 3); with
pantoprazole (𝑁 = 2); with esomeprazole and subsequently
pantoprazole (𝑁 = 2); and with pantoprazole and subse-
quently lansoprazole (𝑁 = 2). In contrast, hypomagnesemia
did not recur in 32 patients following switching to a histamine
type-2 receptor antagonist: ranitidine (𝑁 = 29), famotidine
(𝑁 = 2), and cimetidine (𝑁 = 1).
3.3. Case-Control, Cross-Sectional Studies. The association
between proton-pump inhibitors and metabolism of
magnesium was addressed in 14 case-control, cross-sectional
studies, as given in Table 2. An association was found
uniquely in 10 of them. Six reports found that the use of
proton-pump inhibitors is associated per se with a tendency
towards hypomagnesemia [8, 10, 11, 13, 14, 18]. Two reports
found that the tendency towards hypomagnesemia is more
pronounced in patients concurrently treated with either
diuretic [13, 18] or carboplatin and cisplatin [11]. Danziger
et al. [7] found that hypomagnesemia occurs exclusively in
patients concurrently taking diuretics. Furthermore, two
reports found a relevant tendency to hypomagnesemia in
patients with poor renal function treated with proton-pump
inhibitors [5, 15].
William et al. [17] found an association between the use of
proton-pump inhibitors and decreased urinary magnesium
excretion (a finding that likely reflects a decreased intestinal
magnesium uptake).
Finally, three of the aforementioned studies did not find
any relationship between magnesium and histamine type-2
receptor antagonists [7, 14, 18].
3.4. United States Food and Drug Administration Data. The
reports submitted to the Adverse Event Reporting System
of the United States Food and Drug Administration were
recently examined to address the association between use of
proton-pump inhibitors and hypomagnesemia [63]. Between
1997 and 2012, 66,102 subjects were identified as experiencing
at least one adverse effect while taking a proton-pump
inhibitor. Among the mentioned subjects, 693 (=1.0%) were
reported to have hypomagnesemia. Subjects aged ≥65 years
were at increased risk of hypomagnesemia (𝑃 < 0.001).
Finally, there was a strong (𝑃 < 0.001) association between
occurrence of hypomagnesemia and that of hypocalcemia
or hypokalemia. Two thirds (𝑁 = 461) of the hypomagne-
semia cases occurred in subjects treated with omeprazole or
esomeprazole, the most frequently prescribed proton-pump
inhibitors.
4. Discussion
Thiswork brings together themost recent literature and some
reports identified exclusively from the search engine Google
Scholar. Its results, acquired both in individual case reports
and in case-control, cross-sectional studies, support the
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Table 2: Case-control, cross-sectional studies addressing the potential of proton-pump inhibitors tomodulate themetabolism ofmagnesium.
Reports disclosing a significant relationship between use of these drugs and metabolism of magnesium are bold.
Reference Country Patients Results
Alhosaini et al. [5] USA 62 hemodialysis patients Use of proton-pump inhibitors was associated(P < 0.05) with hypomagnesemia
Biyik et al. [6] Turkey 238 outpatients Magnesemia was similar in users of proton-pumpinhibitors (𝑁 = 154) and nonusers (𝑁 = 84)
Danziger et al. [7] USA 11,490 patients admittedto an intensive care unit
Hypomagnesemia was disclosed exclusively
(P < 0.01) in patients concurrently treated with both
proton-pump inhibitors and diuretics. Use of
histamine type-2 receptor antagonists (with or
without diuretics) was not associated with
hypomagnesemia
El-Charabaty et al.
[8] USA
262 intensive care patients
with cardiac arrhythmias
Use of proton-pump inhibitors prior to admission
was associated with tendency to hypomagnesemia
(r = 0.82)
Faulhaber et al. [9] Brazil 151 internal medicinepatients
No cases of hypomagnesemia were detected on
treatment with proton-pump inhibitors
Gau et al. [10] USA 487 inpatients
Use of proton-pump inhibitors was associated with
lower magnesemia (P < 0.005) and with a 2.5-fold
increased risk of hypomagnesemia
Kim et al. [11] Korea 1356 patients
Magnesemia was lower (P < 0.0001) in users of
proton-pump inhibitors (N = 112) than in nonusers
(N = 1,244). Concurrent treatment with cisplatin
(P < 0.05) or carboplatin (P < 0.01) further
exacerbated hypomagnesemia
Koulouridis et al.
[12] USA
804 well-matched
inpatients
Use of proton-pump inhibitors prior to admission was
not associated with hypomagnesemia
Lindner et al. [13] Switzerland 5,118 emergencydepartment patients
Hypomagnesemia was significantly (P < 0.0001)
associated with the use of proton-pump inhibitor or
both proton-pump inhibitors and diuretics
Markovits et al.
[14] Israel 95,205 outpatients
Users of proton-pump inhibitors (N = 22,458)
presented frequently with hypomagnesemia
(P < 0.005). Use of histamine type-2 receptor
antagonists was not associated with hypomagnesemia
Sumukadas et al.
[15]
United
Kingdom 196 elderly unit patients
Magnesemia was lower (P < 0.05) in users of
proton-pump inhibitors with poor renal function
Van Ende et al. [16] Belgium 512 renal transplantrecipients
Use of proton-pump inhibitors was not a predictor of
hypomagnesemia
William et al. [17] USA 278 outpatients
Magnesiuria was reduced (P < 0.02) in users of
proton-pump inhibitors.Diuretics did not modulate
the effect of proton-pump inhibitors on magnesiuria
Zipursky et al. [18] Canada 1,830 inpatients
Patients admitted with hypomagnesemia were
frequently (odds ratio = 1.43) on proton-pump
inhibitors.Diuretics further exacerbated the
tendency to hypomagnesemia (odds ratio = 1.73). Use
of histamine type-2 receptor antagonists was not
associated with hypomagnesemia
hypothesis that management with proton-pump inhibitors
may cause hypomagnesemia along with hypomagnesiuria,
hypocalcemia, and hypokalemia (see the following list). This
tendency is more pronounced in patients concomitantly
treated with cisplatin, carboplatin, and especially diuretics
and in those with poor renal function.
Clinical and Biochemical Characteristics of Proton-Pump
Inhibitor Associated Hypomagnesemia. Consider the follow-
ing.
(i) Age mostly ≥50 years, duration of treatment ≥1
year, and no emblematical patient profile unique for
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this electrolyte abnormality, being more frequent in
patients concurrently managed with other factors
that may lower magnesemia (e.g., management with
thiazides and loop diuretics, alcohol abuse) and in
those with poor renal function.
(ii) Hypomagnesemia often accompanied by hypocal-
cemic hypoparathyroidism and hypokalemia.
(iii) Hypomagnesemia resolution soon after discontinu-
ing the proton-pump inhibitor, recurring upon read-
ministration or after replacement of one proton-
pump inhibitor with another (=class effect).
(iv) Hypomagnesemia not occurring with histamine
type-2 receptor antagonists (e.g., ranitidine).
The concurrent demonstration of both magnesium defi-
ciency andhypomagnesiuria suggests that impaired intestinal
magnesium absorption is the culprit. This electrolyte abnor-
mality recovers within 4 days after discontinuing the drug;
it recurs upon readministration or after replacement with
another proton-pump inhibitor [64], but it does not develop
with other acid suppressants such as histamine type-2 recep-
tor antagonists. Hypomagnesemia was mostly accompanied
by hypocalcemia and normal or low parathyroid hormone
levels, confirming the existence of a state of secondary
hypoparathyroidism in the most severely hypomagnesemic
patients [65]. A further common laboratory finding was
hypokalemia, a recognized consequence of hypomagnesemia
[65].
In the few individual cases available for such an analysis,
no significant correlation was noted between circulating
magnesium and hypocalcemia or hypokalemia. At least two
factors might account for this unexpected observation. First,
there are sometimes differences among laboratories with
respect to total magnesium determination in blood [65].
Furthermore, circulating magnesium exists in the ionized,
biologically active state and in the undissociated form, either
bound to albumin or complexed to anions such as bicarbon-
ate, citrate, and phosphate [65].
At least three limitations of our study should be men-
tioned. First, the analysis results rather from the small num-
ber of reported subjects affected by proton-pump inhibitor
associated hypomagnesemia. Second, because of the scant
information available on the clinical presentation of mag-
nesium deficiency, the present study does not address this
issue. Third, the underlying mechanisms require further
investigations.
Recognition and management of hypomagnesemia sec-
ondary to long-term treatment with proton-pump inhibitors
mainly rest on two pillars: first, blood magnesium monitor-
ing at least in patients with symptoms or signs consistent
with magnesium deficiency, in those concurrently treated
with other agents that may lower magnesium level, and in
those with poor renal function; second, in patients with
hypomagnesemia, switching to a histamine type-2 receptor
antagonist may be attempted. Further studies are required
to identify whether magnesium supplements or sucralfate
might be prescribed in subjects with proton-pump inhibitor
associated hypomagnesemia.
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